옵션 체인은 다양한 행사가격과 만기일에 대한 Citius Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Citius Pharmaceuticals에 대한 시장 심리를 평가합니다..

Citius Pharmaceuticals (NASDAQ:CTXR) 주식, 옵션 체인

Citius Pharmaceuticals

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

Citigroup analyst Paul Lejuez maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Buy and lowers the price target from $212 to $207.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Owens-Corning, Lowers Price Target to $207

Citigroup analyst Anthony Pettinari maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Neutral and lowers the price target from $82 to $77.

Citigroup Maintains Neutral on Masco, Lowers Price Target to $77

Financial giants have made a conspicuous bullish move on STMicroelectronics. Our analysis of options history for STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) revealed 11 unusual trades.
Delving into the details, we found 54% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $328,100, and 5 were calls, valued at $423,063.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $40.0 for STMicroelectronics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for STMicroelectronics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of STMicroelectronics's whale activity within a strike price range from $25.0 to $40.0 in the last 30 days. 
<h3>STMicroelectronics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736196332_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>STM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.25</td>
<td>$2.1</td>
<td>$2.25</td>
<td>$26.00</td>
<td>$152.4K</td>
<td>479</td>
<td>686</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.4</td>
<td>$1.25</td>
<td>$1.4</td>
<td>$25.00</td>
<td>$126.0K</td>
<td>1.2K</td>
<td>902</td>
</tr>
<tr>
<td>STM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.0</td>
<td>$2.9</td>
<td>$2.9</td>
<td>$28.00</td>
<td>$79.1K</td>
<td>13</td>
<td>489</td>
</tr>
<tr>
<td>STM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.75</td>
<td>$0.7</td>
<td>$0.75</td>
<td>$26.00</td>
<td>$67.5K</td>
<td>8.8K</td>
<td>930</td>
</tr>
<tr>
<td>STM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.55</td>
<td>$0.5</td>
<td>$0.55</td>
<td>$27.00</td>
<td>$66.1K</td>
<td>996</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About STMicroelectronics</h3>
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
After a thorough review of the options trading surrounding STMicroelectronics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of STMicroelectronics</h3>
<ul>
<li>With a trading volume of 5,725,699, the price of STM is up by 7.44%, reaching $26.23.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 17 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest STMicroelectronics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Unpacking the Latest Options Trading Trends in STMicroelectronics

Financial giants have made a conspicuous bullish move on Walgreens Boots Alliance. Our analysis of options history for Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $275,920, and 4 were calls, valued at $144,065.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $9.5 and $12.5 for Walgreens Boots Alliance, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Walgreens Boots Alliance stands at 17582.17, with a total volume reaching 20,647.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Walgreens Boots Alliance, situated within the strike price corridor from $9.5 to $12.5, throughout the last 30 days.
<h3>Walgreens Boots Alliance Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736196327_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.49</td>
<td>$0.41</td>
<td>$0.49</td>
<td>$9.50</td>
<td>$61.8K</td>
<td>262</td>
<td>1.3K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.7</td>
<td>$0.67</td>
<td>$0.67</td>
<td>$10.00</td>
<td>$59.7K</td>
<td>29.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>WBA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$0.74</td>
<td>$0.73</td>
<td>$0.73</td>
<td>$10.00</td>
<td>$54.9K</td>
<td>29.0K</td>
<td>1.9K</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.88</td>
<td>$1.85</td>
<td>$1.88</td>
<td>$10.00</td>
<td>$46.8K</td>
<td>20.6K</td>
<td>690</td>
</tr>
<tr>
<td>WBA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.95</td>
<td>$1.85</td>
<td>$1.95</td>
<td>$10.00</td>
<td>$39.0K</td>
<td>20.6K</td>
<td>327</td>
</tr>
</tbody>
</table>

<h3>About Walgreens Boots Alliance</h3>
Walgreens Boots Alliance is one of the largest retail pharmacy chains in the US, with over 8,000 locations. Nearly three quarters of Americans live within five miles of a Walgreens location. Roughly two thirds of revenue is generated from prescription drug sales; Walgreens makes up 20% of total prescription revenue in the US. Walgreens also generates sales from retail products (general wellness consumables and its own branded merchandise), European drug wholesale, and healthcare. With more locations incorporating additional services like Health Corner and Village Medical, Walgreens creates an omnichannel experience for patients and positions itself as a one-stop healthcare provider.
After a thorough review of the options trading surrounding Walgreens Boots Alliance, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Walgreens Boots Alliance</h3>
<ul>
<li>Trading volume stands at 13,249,376, with WBA's price up by 1.58%, positioned at $9.65.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 4 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walgreens Boots Alliance with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Decoding Walgreens Boots Alliance's Options Activity: What's the Big Picture?

WIIM

GOOG

GOOGL

Alphabet shares are trading higher after Wedbush raised its price target from $210 to $220 while maintaining an Outperform rating.

Whales with a lot of money to spend have taken a noticeably bullish stance on Advanced Micro Devices.
Looking at options history for Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) we detected 123 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 29 are puts, for a total amount of $9,677,722 and 94, calls, for a total amount of $7,942,802.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $200.0 for Advanced Micro Devices over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Advanced Micro Devices's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Advanced Micro Devices's substantial trades, within a strike price spectrum from $65.0 to $200.0 over the preceding 30 days.
<h3>Advanced Micro Devices Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736196322_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$43.4</td>
<td>$43.25</td>
<td>$43.25</td>
<td>$100.00</td>
<td>$1.1M</td>
<td>9.3K</td>
<td>9.7K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.8</td>
<td>$4.75</td>
<td>$4.8</td>
<td>$150.00</td>
<td>$235.1K</td>
<td>26.5K</td>
<td>4.0K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$42.6</td>
<td>$42.4</td>
<td>$42.6</td>
<td>$100.00</td>
<td>$213.0K</td>
<td>9.3K</td>
<td>13.6K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$42.5</td>
<td>$42.25</td>
<td>$42.44</td>
<td>$100.00</td>
<td>$191.2K</td>
<td>9.3K</td>
<td>12.9K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$14.9</td>
<td>$14.75</td>
<td>$14.9</td>
<td>$145.00</td>
<td>$149.0K</td>
<td>1.0K</td>
<td>114</td>
</tr>
</tbody>
</table>

<h3>About Advanced Micro Devices</h3>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
After a thorough review of the options trading surrounding Advanced Micro Devices, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Advanced Micro Devices Standing Right Now?</h3>
<ul>
<li>With a volume of 38,019,563, the price of AMD is up 3.69% at $130.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>What Analysts Are Saying About Advanced Micro Devices</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $156.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Advanced Micro Devices, which currently sits at a price target of $158. 
&#x2A; An analyst from B of A Securities downgraded its action to Neutral with a price target of $155. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Advanced Micro Devices, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Advanced Micro Devices Unusual Options Activity For January 06

BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) has outperformed the market over the past 5 years by 18.86% on an annualized basis producing an average annual return of 31.67%. Currently, BJ's Wholesale Club has a market capitalization of $11.95 billion. 
Buying $1000 In BJ: If an investor had bought $1000 of BJ stock 5 years ago, it would be worth $3,983.71 today based on a price of $90.47 for BJ at the time of writing.
<h3>BJ's Wholesale Club's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736196314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning BJ's Wholesale Club Stock In The Last 5 Years

Citigroup analyst Anthony Pettinari maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Buy and lowers the price target from $701 to $600.

Citigroup Maintains Buy on Martin Marietta Materials, Lowers Price Target to $600

Citigroup analyst Anthony Pettinari maintains Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a Neutral and lowers the price target from $196 to $150.

Citigroup Maintains Neutral on Lennar, Lowers Price Target to $150

Luna Innovations Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) shares are trading lower by 45% to $1.12 Monday afternoon after the company announced its stock will be <a href="https://www.benzinga.com/pressreleases/25/01/b42812784/luna-innovations-stock-to-be-suspended-from-nasdaq-listing">suspended</a> from the Nasdaq.
What Else: Luna Innovations&#8217; stock will delisted from Nasdaq after failing to meet the SEC&#8217;s March 2025 deadline for delinquent filings. The company anticipates its shares will trade on the OTC Expert Market following the suspension. 
Despite the delisting, Luna emphasized that its business operations remain unaffected and that it continues to support customers and partners.
CEO Kevin Ilcisin acknowledged delays in the restatement process but highlighted operational improvements and key achievements in late 2024. 
Luna says the company remains focused on delivering high-quality products and services. The company plans to share a business update later in January, including preliminary revenue and booking results for fiscal year 2024.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42826154/wall-street-rallies-chipmakers-soar-ahead-of-nvidias-huang-speech-bitcoin-reclaims-100000-whats-driving-markets-monday">Wall Street Rallies, Chipmakers Soar Ahead Of Nvidia&#8217;s Huang Speech, Bitcoin Reclaims $100,000: What&#8217;s Driving Markets Monday?</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LUNA has a 52-week high of $7.92 and a 52-week low of $1.11.

Why Luna Innovations Shares Are Down 45% Today

Citigroup analyst Anthony Pettinari maintains Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) with a Buy and lowers the price target from $43 to $39.

Citigroup Maintains Buy on Forestar Group, Lowers Price Target to $39

BTAI

BioXcel Therapeutics shares are trading higher. Canaccord Genuity maintained a Buy rating on the stock.

NRXP

NRX Pharmaceuticals shares are trading higher after the company announced it will acquire Dura Medical with HOPE Therapeutics. Additionally, the company signed a binding term sheet with HOPE with $27 million to fund further acquisitions and pharmaceutical operations.

Running a business can be tough, but when family is involved, it gets even more complicated. That's exactly what happened to a small-business owner who called into Dave Ramsey's EntreLeadership <a href="https://www.youtube.com/watch?v=BIq3QkWygTk">podcast</a> seeking advice. Gary's problem is that his father owns 51% of their successful dewatering company, takes $20,000 a month and doesn't contribute to the business at all.
<h2 class="wp-block-heading">The Backstory</h2>
Gary and his dad started their business 15 years ago, growing it from nothing into a $3 million annual success story. But while Gary works hard managing their team of 12 employees, his father's involvement has dwindled to zero. Yet, his dad still rakes in a hefty monthly payout – the same amount Gary takes – plus his share of any year-end profits.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Gary's frustration boiled over. In 2019, he tried to buy his dad out, but the deal fell through. Now, he feels stuck. He's running the company but can't grow it because so much money goes to his absent father.
<h2 class="wp-block-heading">Dave Ramsey's Tough Love</h2>
Dave's advice started with a wake-up call: "Quit whining." He told Gary the key to resolving this issue is separating ownership from employment. Owners are entitled to profit distributions, not salaries unless they're actively working in the business. This means Gary should pay himself a proper <a href="https://www.benzinga.com/news/24/05/38936090/top-5-highest-paid-american-ceos-of-2023">CEO salary</a>, something like $250,000 a year, given the company's revenue. After paying salaries, the remaining profits should be distributed based on ownership, with 51% going to his dad and 49% to Gary.
The current setup blurs the lines between salary and profit, which needs to change so that everyone's role and compensation are transparent. &#8220;Once it&#8217;s set up that way, then you could still have the complaint that your dad won&#8217;t let you buy him out and that&#8217;s another discussion,&#8221; said Ramsey.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Gary also needs to have a <a href="https://www.benzinga.com/startups/24/09/40970011/kevin-olearys-dad-warned-him-hed-starve-to-death-if-he-pursued-his-passion-getting-an-mba-ended-up-c">direct conversation with his dad – </a>without being confrontational – to explain why the current system isn't sustainable. Dave explained how important it is to show respect to his dad as the person who helped start the business.&nbsp;
Gary should recognize his dad's role in building the company and make the buyout a way to honor both of their efforts. &#8220;Your dad doesn't feel like you've been nice and you saying that is not going to do anything but rile him up,&#8221; Ramsey advised.
<h2 class="wp-block-heading">The Path to a Buyout</h2>
Gary's ultimate goal is to buy out his father and he's already taken some smart steps. He's had the business valued and hired a joint attorney to help facilitate the deal. But Dave warned him not to let lawyers drive the process. Instead, he and his dad need to hash out the terms together over a cup of coffee, with the attorney helping to finalize the details.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.
<h2 class="wp-block-heading">A Lesson for All Business Owners</h2>
Gary's dilemma is all too common in family businesses. Dave's advice highlighted three critical areas. First, ownership and employment should be separate. If someone isn't working in the business, they shouldn't be taking a salary. Profit distributions should be based on ownership, not employment status.
Second, <a href="https://www.benzinga.com/news/24/12/42714233/ive-got-a-phd-in-d-u-m-b-dave-ramsey-reveals-how-he-built-his-300-million-business">planning for succession</a> early is fundamental. Exact succession and transition plans can help avoid messy situations like the one Gary is facing. Establishing these plans ahead of time ensures everyone knows how the business will be passed down and how roles will change.
Finally, respecting the business&#8217;s founders is key. Honoring those who built the company cultivates goodwill and can ease difficult conversations. On the other hand, shaming them or dismissing their contributions often leads to conflict and unresolved issues.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

'You've Completely Screwed This Up' – A Business Owner Asks Dave Ramsey For Help: My Dad Rakes In $20,000 A Month And Contributes Nothing

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher Monday following the announcement that the company will play a key role in Kratos Defense &amp; Security Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) $1.45 billion <a href="https://www.benzinga.com/news/contracts/25/01/42816275/kratos-defense-stock-is-rising-monday-whats-going-on">MACH-TB 2.0 contract</a>.
What To Know: Kratos, a defense technology company, on Monday secured a five-year contract for Multi-Service Advanced Capability Hypersonic Test Bed (MACH-TB) 2.0, a project designed to enhance the U.S. hypersonic flight testing infrastructure. 
The initiative, established under the Office of the Under Secretary of Defense for Research and Engineering&#8217;s National Hypersonic Initiative 2.0, aims to bridge the gap between ground testing and full-scale hypersonic system testing, reducing risks and accelerating development.
Kratos will lead Task Area 1 of the MACH-TB 2.0 project, focusing on systems engineering, integration and testing. Rocket Lab will provide air launch services as part of a larger team that includes Leidos, Stratolaunch and other subcontractors. This effort will support the increased frequency of hypersonic flight tests needed for national security objectives.
Check This Out: <a href="https://www.benzinga.com/general/space/25/01/42828631/exclusive-rocket-lab-intuitive-machines-redwire-or-ast-spacemobile-33-of-readers-pick-this-space-stock-for-2025">EXCLUSIVE: Rocket Lab, Intuitive Machines, Redwire Or AST SpaceMobile? 33% Of Readers Pick This Space Stock For 2025</a>
Kratos&#8217; leadership emphasized the importance of the program in advancing affordable hypersonic technologies and highlighted the contract as the largest in the company&#8217;s history. The MACH-TB 2.0 program is expected to be a significant driver of future growth for Kratos, which also cited its existing hypersonic capabilities as a key factor in securing the contract.
"With the recent successes of our low-cost Erinyes Hypersonic Flyer and Zeus Solid Rocket Motors, Kratos is a leader in the testing and fielding of hypersonic systems. We are very excited to bring this unmatched expertise to the MACH-TB 2.0 program,&#8221; said Dave Carter, President of Kratos Defense and Rocket Support Services Division.
Rocket Lab shares are up nearly 200% over the past three months. The company reported better-than-expected financial results in mid-November and announced a multi-launch agreement with a confidential customer.
Rocket Lab guided for fourth-quarter revenue in the range of $125 million to $135 million. Rocket Lab is expected to report fourth-quarter earnings in February. Analysts currently expect the company to report a loss of 10 cents per share on revenue of $130.57 million, according to estimates from <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
RKLB Price Action: Rocket Lab shares were up 1.03% at $29.02 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06140256/Screenshot-2025-01-06-at-14.02.24-1024x524.png" alt="" class="wp-image-720448" style="width:520px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06140256/Screenshot-2025-01-06-at-14.02.24-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06140256/Screenshot-2025-01-06-at-14.02.24-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06140256/Screenshot-2025-01-06-at-14.02.24-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/06140256/Screenshot-2025-01-06-at-14.02.24.png 1520w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42826690/pudgy-penguins-coin-pengu-surge-outperforms-dogecoin-shiba-inu-pepe-one-of-the-best-for-this-cycle-trader-says">Pudgy Penguins Coin PENGU Surge Outperforms Dogecoin, Shiba Inu, Pepe: &#8216;One Of The Best For This Cycle,&#8217; Trader Says</a></li>
</ul>
Image via Shutterstock.

Contracts

Movers

KTOS

RKLB

Rocket Lab Shares Are On The Rise Today: What's Going On?

Citigroup analyst Anthony Pettinari maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Neutral and lowers the price target from $221 to $189.

FERG

Citigroup Maintains Neutral on Ferguson Enterprises, Lowers Price Target to $189

Macro Notification

Market Summary

General

$BTC

MSFT

NVDA

Benzinga Market Summary: Bitcoin Rises, Trudeau To Resign As Liberal Party Leader, Tech Stocks Rise Amid CES 2025 And Microsoft AI Investment Plans

Citigroup analyst Anthony Pettinari maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Neutral and lowers the price target from $185 to $152.

Citigroup Maintains Neutral on D.R. Horton, Lowers Price Target to $152

Citigroup analyst Anthony Pettinari maintains CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) with a Buy and lowers the price target from $120 to $115.

Citigroup Maintains Buy on CRH, Lowers Price Target to $115

Shares of crypto-related companies, including MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) and Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), are trading sharply higher on Monday as Bitcoin surged past the $100,000 mark, reigniting bullish sentiment <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42826154/wall-street-rallies-chipmakers-soar-ahead-of-nvidias-huang-speech-bitcoin-reclaims-100000-whats-driving-markets-monday">in the cryptocurrency market.</a>
What To Know: Bitcoin crossed the $100,000 mark for the first time,<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42822776/bitcoin-jumps-past-102000-experts-see-classic-correction-eye-109000-high"> reaching a high of $102,482</a> during early trading on Monday. This 3.2% increase pushed the total cryptocurrency market capitalization above $3.5 trillion, marking its highest level since mid-December.
Analysts attribute the rise to the completion of a &#8220;classic correction,&#8221; with signs pointing to potential further gains. Market sentiment indicators, including one tracking &#8220;extreme greed,&#8221; potentially reflect strong buying interest in Bitcoin as it moves past this psychological milestone.
Ethereum also rose 3% to $3,736, while other cryptocurrencies like Solana and Avalanche gained 4% and 7%, respectively. Experts suggest Bitcoin could gain additional momentum if it breaks past $109,000, a key resistance level. 
According to Alex Kuptsikevich of FxPro, a decisive break above this threshold could confirm the resumption of a broader uptrend and accelerate Bitcoin&#8217;s growth further. For now, its recent rise underscores the continued focus on the cryptocurrency as a driver of broader market activity.
Price Action: MicroStrategy shares were up 9.79% to $372.90, Hut 8 shares were up 9.15% to $26.37 and Coinbase shares were up 6.92% to $289.37 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
Image Via Shutterstock.

COIN

MSTR

Crypto-Related Shares Are Surging Today: What's Going On?

D. Boral Capital downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy without a price target following the company's announcement of a 1-for-2...

Citius Pharmaceuticals downgraded to Hold from Buy at D. Boral Capital

Citius Pharmaceuticals (CTXR) announced that the company held a constructive in-person Type C meeting with the U.S. FDA. The meeting followed succe...

Citius Pharmaceuticals reports 'constructive' FDA Type C meeting on Mino-Lok

19:50 EST Citius Pharmaceuticals (CTXR) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...

Citius Pharmaceuticals trading halted, news pending

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CTXR stock, giving a Buy rating on November 12. Michael Okunewitch ha...

Promising Outlook for Citius Pharmaceuticals: Buy Rating Affirmed Amid Product Potential and Strategic Developments

Citius Pharma ( ($CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pha...

Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharmaceuticals GAAP EPS of -$5.97

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which i...

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) shares were under pressure...

Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusi...

Citius Oncology to explore strategic alternatives

AMTM

ARQT

ARTV

AXSM

CTOR

HSAI

KULR

NAMS

NUVL

RCKT

RHHBY

RHHVF

SEAT

TLRY

TTWO

VCSA

WKSP

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Earnings

Press Releases

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Comments

Citius Pharmaceuticals

Citius Pharmaceuticals (CTXR) 옵션

Citius Pharmaceuticals (NASDAQ:CTXR) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌